Roche’s Alecensa Goes Up Against Zykadia with First-Line NSCLC US FDA Approval
Executive Summary
Expanded US approval for Alecensa in ALK-positive NSCLC will stand the product in good stead as it helps make up for upcoming biosimilar threat to Avastin, Rituxan and Herceptin.
You may also be interested in...
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
Can Takeda's Alunbrig Take On Roche's Alecensa In First-Line ALK-Positive Lung Cancer?
Takeda's Phase III win over Pfizer's Xalkori leaves oncologists cheering, but hankering for a head-to-head study against Alecensa, which is becoming the standard of care in the US for first-line ALK+ NSCLC.
Roche’s External Control Arms Show What Real-World Evidence Can Look Like In Practice
With Flatiron, Roche is at the forefront of the emerging field of RWE. Roche Pharma President O’Day described how the company is using such data in the real world of regulation and reimbursement.